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Nitric oxideResveratrol (RESV) is a polyphenol with pleiotropic effects that include reduction of oxidative stress and in-
creased vascular nitric oxide (NO) production. However,whether or not RESV can prevent rises in blood pressure
(BP) is controversial and remains to be ﬁrmly established. The purpose of this study was to determine whether
RESV attenuates elevated BP and subsequent adaptive cardiac hypertrophy and to better understand the mech-
anisms involved. The spontaneously hypertensive rat (SHR) and the angiotensin (Ang)-II infused mouse were
used as hypertensive models. Compared to a standard control diet, consumption of diets containing RESV by
SHRs and Ang-II hypertensive mice, markedly prevented rises in systolic BP. In addition, ﬂow-mediated vasodi-
lation was signiﬁcantly improved by RESV in SHRs. RESV also reduced serum and cardiac levels of the lipid
peroxidation by-product, 4-hydroxy-2-nonenal in the hypertensive rodents and inhibited the production of
superoxide in human-derived endothelial cells. Analysis of mesenteric arteries from SHRs and Ang-II infused
mice demonstrated that RESV increased endothelial NO synthase (eNOS) phosphorylation by enhancing the
LKB1/adenosine monophosphate (AMP)-activated protein kinase (AMPK) signal transduction pathway. More-
over, RESV reduced hypertrophic growth of themyocardium through reduced hemodynamic load and inhibition
of the p70 S6 kinase pro-hypertrophic signaling cascade. Overall, we show that high dose RESV reduces oxidative
stress, improves vascular function, attenuates high BP and prevents cardiac hypertrophy through the preserva-
tion of the LKB1–AMPK–eNOS signaling axis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The World Health Organization estimates that hypertension affects
approximately 25% of adultsworldwide [1]. Despite continued improve-
ment in the treatment and management of hypertension, 20–30% of
hypertensive patients are resistant to blood pressure (BP) reduction
with the maximum tolerated dose of at least three anti-hypertensive
drugs [2]. In addition, growing numbers of individualswith themetabol-
ic syndrome are contributing to the rising prevalence of hypertension.
Since hypertension is associated with severe complications, including
end organ damage, arteriosclerosis, left ventricular (LV) hypertrophyAng-II, angiotensin-II; BP, blood
4-hydroxy-2-nonenal; HUVEC,
ht/tibia length; IVRT, intraven-
eft ventricular; LVEF, LV ejection
, resveratrol; ROS, reactive oxy-
ch Centre, University of Alberta,
14; fax: +1 780 492 9753.
.
rights reserved.and stroke [3], it is imperative that additional treatments that also pre-
vent the cardiovascular complications are developed.
Although the pathogenesis of hypertension can be inﬂuenced by
multiple factors [4], the development of vascular dysfunction precedes
the development of elevated BP [4]. Of importance, oxidative stress
has been shown to play a crucial role in the development of vascular
dysfunction [5]. While oxidative stress alters a variety of cellular signal-
ing cascades and cellular functions [6], oxidative stress reduces the bio-
availability of vasodilatory molecules such as nitric oxide (NO) [7].
In addition, oxidation of membrane lipids can lead to the production
of reactive lipid peroxidation products such as 4-hydroxy-2-nonenal
(HNE), which damages proteins in the cardiovascular system (see [8]
for review).
HNE levels are markedly elevated in the circulation aswell as in car-
diac tissue in hypertensive rodents [9] and humans [10]. At the molec-
ular level, recent evidence has demonstrated that HNE exerts some of
its negative biological effects on the heart through the direct modiﬁca-
tion and inhibition of LKB1 activity and the inhibition of its downstream
substrate, AMP-activated protein kinase (AMPK) [11,12]. While AMPK
regulates NO production through the phosphorylation and activation
of endothelial NO synthase (eNOS) [13], it is unknown whether
1724 V.W. Dolinsky et al. / Biochimica et Biophysica Acta 1832 (2013) 1723–1733elevated HNE levels in hypertensive rodents also inhibit the LKB1–
AMPK–eNOS signal transduction cascade in endothelial cells or vascular
tissues of hypertensive rodents.
We recently showed that calorie restriction (CR) prevents the signif-
icant rise of BP in the spontaneously hypertensive rat (SHR) [14] and that
the subsequent positive vascular adaptations involved increased NO bio-
availability through stimulation of AMPK–eNOS signaling [14]. However,
lifestyle modiﬁcations, such as CR, require signiﬁcant long-term patient
compliance, which may be difﬁcult to achieve. The utilization of small
molecules that activate similar molecular and signal transduction path-
ways as CR could provide novel therapeutic approaches for hypertension.
Interestingly, the natural polyphenolic molecule, resveratrol (RESV),
mimics many of the molecular and biological effects of CR [15]. More-
over, we showed that RESV prevented HNE-mediated inhibition of the
LKB1–AMPK signaling axis in cardiomyocytes [11]. However, the ability
of RESV to regulate BP is unclear. Some studies showed that RESV
had no effect on BP [11,16–19], while other reports indicate that RESV
lowered BP [20–23]. Due to these divergent ﬁndings, the purpose of
this study is to clarify how RESV administration inﬂuences vascular func-
tion and BP in the SHR model of genetically programmed hypertension
and the angiotensin (Ang)-II infused hypertensive mouse to investigate
the effects of RESV on BP regulation in two distinct non-obese models
of hypertension. In addition, we investigated whether the effects of
RESV on BP corresponded with lower levels of HNE and the activation
of the LKB1–AMPK–eNOS signal transduction cascade that could rescue
NO bioavailability.
2. Material and methods
2.1. Materials
Most antibodies were purchased from either Cell Signaling Technol-
ogy or Santa Cruz Biotechnology. The anti-nitrosocysteine antibodywas
purchased from Abcam (Cambridge, MA). Most other cell culture re-
agents and chemicals were purchased from Sigma. Fetal bovine serum
was obtained from Invitrogen (Carlsbad, CA). Resveratrol was pur-
chased from Lalilab (Durham, NC).
2.2. Animal care and diets
The University of Alberta Animal Policy andWelfare Committee ad-
heres to the principles of biomedical research involving animals devel-
oped by the Council for International Organizations of Medical Sciences
(CIOMS). SHRs and C57BL/6 mice were obtained from Charles River
Laboratories (St. Foy, QC). Rodents had ad libitum access to water and
were fed the AIN93G standard chow (control) diet or an AIN93G stan-
dard chow diet that contained 4 g RESV/kg diet (Dyets Inc., Bethlehem,
PA), a dosage that was consistent with previous studies [24,25]. For
SHRs, the dosage of RESV was equivalent to ~146 mg RESV/kg/day
and for mice, the dosage was equivalent to ~320 mg RESV/kg/day.
Alzet Osmotic Micro-pumps (Cupertino, CA) were implanted into
C57BL/6 mice for the delivery of saline or Ang-II (1.4 mg/kg/day) by a
small incision that was made dorsal interscapularis, to form a small
subcutaneous pocket. SHRs consumed the diets for 5 weeks and mice
consumed the diets for twoweeks following implantation of the osmotic
mini-pumps.
2.3. Analysis of tissues
Blood was collected from rodents by cardiac puncture and the
tissues were freeze-clamped in liquid nitrogen as described previous-
ly [11,24]. Tissues were homogenized and the protein concentration
was assayed using Bradford Protein Reagent. 15–20 μg of protein was
used for SDS–PAGE and immunoblot analysis. HNE-protein adducts
were quantiﬁed using the OxiSelect HNE-His Adduct ELISA Kit (CellBiolabs, San Diego, CA) from 1 μg of protein lysates from heart tissue
or serum samples according to the manufacturer's instructions.
2.4. In vivo assessment of cardiac and vascular function
Transthoracic echocardiographywas performed according to our pre-
viously reported procedures [14] on mildly anesthetized (sedated with
3% and maintained at 1–1.5% isoﬂuorane) SHRs at 8 and 15 weeks of
age using a Vevo 770 High-Resolution Imaging System equipped with a
17.5-MHz transducer (Visual Sonics, Toronto, ON). Formice, transthorac-
ic echocardiographywas performed on 24 and 26-week oldmice using a
30-MHz transducer. Flow-mediated vasodilation of the femoral artery
was performed according to procedures we described previously [14].
BP was recorded using a telemetric BP recording device, TA11PA-C10
(Data Science International, St. Paul, MN), and heart rate (HR), and
mean arterial (MAP), systolic (SP), and diastolic (DP) pressures were
measured weekly using PowerLab 4/30 Acquisition and LabChart 7 soft-
ware (ADInstruments, Colorado Springs, CO). See online supplement for
detailed methods.
2.5. Human umbilical vein endothelial cell (HUVEC) culture
Cells were isolated from human umbilical cords obtained from
the Royal Alexandra Hospital in Edmonton, AB. The protocol was ap-
proved by the University of Alberta Ethics Committee and conformed
to the principles outlined in the Declaration of Helsinki and also Title
45, US Code of Federal Regulations, Part 46, Protection of Human Sub-
jects. All subjects provided written informed consent. HUVECs were
grown at 37 °C with 5% CO2/95% air in M199 medium supplemented
by 20% fetal bovine serum, L-Glutamine, Penicillin–Streptomycin and
1% endothelial cell growth supplement. Superoxide detection and
S-nitrosocysteine measurements were performed as described previ-
ously [26]. See online supplement for detailed methods.
2.6. Statistical analysis
Data are expressed as mean ± standard error of the mean (S.E.M.).
Comparisons between treatment groups were performed using the un-
paired Student's two-tailed t-test or analysis of variance (ANOVA) with
a Bonferroni post-hoc test of pairwise comparisons between groups,
where appropriate. The repeated measures test was used wherever
applicable. A probability value of b0.05 was considered signiﬁcant.
3. Results
3.1. Resveratrol improves vascular function and prevents the rise of BP in
hypertensive rodents
ARESV containing diet was administered to SHRs at 10 weeks of age
and SHRsweremaintained on this diet until theywere 15 weeks of age.
These ages were selected since SHRs advance from mild (10 weeks of
age) to pronounced hypertension (15 weeks of age) during this period
and display compensatory increases in concentric LVH [11]. Consistent
with our previous ﬁndings [11], RESV had no effect on body weight
in the SHRs at 15 weeks of age (Table S1). Since recent work has
established that RESV improves vascular function using isolated vessels
ex vivo [17,23,27,28], we investigatedwhether RESV could also improve
vascular function in the SHR in vivo. To do this, we initiated RESVwhen
the SHRs were mildly hypertensive, but prior to developing increased
LVwall thickness (Table S1) and thenmonitored femoral artery vasodi-
lation andﬂowvelocity using ultrasound at 15 weeks of age. Hyperemic
vasodilation was greater in the RESV-SHRs compared to the control-
SHRs, following temporary ischemia (Fig. 1A). Furthermore, femoral
artery blood ﬂow velocity following temporary ischemia was signiﬁ-
cantly higher in RESV-SHRs compared with control-SHRs (Fig. 1B) and
the effective arterial elastance (Fig. 1C) was signiﬁcantly reduced in
Fig. 1. In vivo vascular function and telemetric blood pressure (BP) recordings of control and resveratrol (RESV) treated spontaneously hypertensive rats (SHR). Femoral artery diameter
relative to baseline following 5 min temporary ischemia of the hindlimb (A), femoral artery Doppler ﬂow velocity following occlusion measured relative to baseline (B) and effective
arterial elastance (C) in 15 week-old SHRs (5-week RESV). Weekly BP recordings were made in 10–15 week-old SHRs during the 5-week RESV treatment protocol and for two weeks
following cessation of RESV in 16 and 17 week-old SHRs. Mean arterial (D), systolic (E) and diastolic (F) BPs. Values are the mean ± S.E.M. (n = 5). *Signiﬁcant difference (p b 0.05)
between Control-SHR and RESV-SHR rats using a two-way ANOVA Bonferroni post-test with repeated measures.
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peripheral resistance. As expected from improved vascular function,
RESV treatment prevented the signiﬁcant rise in MAP, as well as SP
and DP in the SHRs (Fig. 1D–F). In agreement with RESV being respon-
sible for the BP effects, removal of RESV from SHRs resulted in a rapid
(2 weeks) and striking rise in BP in previously treated SHRs to levels
observed in the control-SHRs (Fig. 1D–F).
To conﬁrm that the RESV-mediated effects on BP were not
conﬁned to the SHR model or to rats in general, we evaluated RESV
in a mouse model of Ang-II induced hypertension. Elevated systemic
levels of Ang-II signiﬁcantly increased SP in the mice compared to
saline-infused mice (Fig. 2A), though not DP (Fig. 2B). Consistent
with the effects of RESV in the SHRs, the addition of RESV to the diets
of Ang-II infused mice prevented the signiﬁcant rise of SP (Fig. 2A),
though RESV did not affect DP (Fig. 2B). RESV also improved in vivo vas-
cular function in Ang-II infused mice, as determined by femoral artery
ﬂow velocity using Doppler ﬂow ultrasound. Mice infused with Ang-II
had signiﬁcantly reduced femoral artery blood ﬂow velocity following
temporary ischemia, compared with saline controls (Fig. 2C). In the
Ang-II infused mice, RESV signiﬁcantly increased the femoral artery
bloodﬂowvelocity following temporary ischemia (Fig. 2C) andRESV at-
tenuated the Ang-II induced rise in effective arterial elastance (Fig. 2D).
These observations demonstrate that RESV administration improved
vascular function and prevented the rise in BP in two distinct rodent
models of hypertension.3.2. RESV increases arterial eNOS and AMPK activities in hypertensive
rodents
Based on the effects of RESV on the vascular function of the hyper-
tensive rodents, we hypothesized that endogenous NO production
was higher in RESV-treated rodents. To investigate this, we measured
phosphorylated serine-1177 eNOS (P-eNOS) as a surrogate marker of
eNOS activity. Increased P-eNOS was observed in mesenteric arteries
isolated from RESV-SHRs compared to control-SHRs (Fig. 3A). In
addition, Ang-II infusion was associated with lower P-eNOS levels in
mesenteric arteries and this decrease was prevented by RESV
(Fig. 3B). These observations likely reﬂect a RESV-induced increase
of NO bioavailability in the two distinct hypertensive models.
Since AMPK has been shown to be activated by RESV [11,29] and
AMPK activates eNOS by phosphorylating the serine-1177 residue
[13], we measured the levels of phosphorylated AMPK at its activation
site, threonine-172 (P-AMPK). P-AMPK levels were 3-fold higher in
the arteries of RESV-SHR compared to control-SHRs (Fig. 3C). Corre-
spondingly, RESV increased P-AMPK in the arteries of saline and Ang-II
infusedmice (Fig. 3D). As phosphorylation and stimulation of AMPK oc-
curs via the action of its upstreamactivating kinase, LKB1, we also inves-
tigated the activity of LKB1 using phosphorylation of LKB1 at serine-428
(P-LKB1) as a surrogate marker of LKB1 activity [30]. RESV increased
P-LKB1 3-fold in SHRs compared with controls (Fig. 3E). In addition,
RESV increased P-LKB1 in the saline and Ang-II infused mice (Fig. 3F).
Fig. 2. Blood pressure (BP) and vascular function in angiotensin (Ang)-II induced hypertension. BP recordings were made at baseline and 2 weeks following the initiation of Ang-II
infusion (1.4 mg/kg/day) and RESV (4 g/kg of food) treatments in C57BL/6 mice. In vivo telemetric systolic (A) and diastolic (B) BP recordings. Following 2 weeks of treatments,
femoral artery Doppler ﬂow velocity following occlusion was measured relative to baseline (C). Effective arterial elastance (D). Values are the mean ± S.E.M., (n = 6 mice).
*Signiﬁcant difference (p b 0.05) between measurements taken at baseline and following 2 weeks of Ang-II and RESV treatments. #Signiﬁcant difference (p b 0.05) between
Week 2 AngII-CON (control) and AngII-RESV groups using a one-way ANOVA. §Signiﬁcant difference (p b 0.05) between the AngII-CON group and all other groups of mice
using a two-way ANOVA Bonferroni post-test with repeated measures.
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oxidative stress and LKB1–AMPK–eNOS signaling. Previous work dem-
onstrated that the lipid peroxidation by-product, HNE, is elevated in
SHRs [9] and inhibits LKB1 activity [11]. Therefore we measured plasma
HNE levels in both of ourmodels. In the present study, we observed that
the circulating HNE levels were signiﬁcantly lower in RESV-SHRs com-
pared to control-SHRs (Fig. 3G). Moreover, serum HNE levels were
signiﬁcantly elevated in themice infusedwith Ang-II compared to saline
infusedmice (Fig. 3H).More importantly, this Ang-II induced increase in
serumHNE levels was attenuated by RESV (Fig. 3H), which corresponds
with elevated LKB1-AMPK-eNOS signaling in the arteries of
hypertensive rodents treated with RESV (Fig. 3A–F).3.3. RESV prevents the deleterious effects of HNE on endothelial NO
generation
In order to determinewhether HNE regulates endothelium superox-
ide and NO levels via the LKB1-AMPK-eNOS signal transduction path-
way in the absence of pre-existing hypertension and/or elevated
Ang-II (i.e. wasHNE sufﬁcient to recapitulate the alterations in signaling
thatwe observed inmesenteric arteries fromhypertensive rodents), we
utilized a human-derived HUVEC cell culture system. As expected, HNE
potentiated the production of superoxide in HUVECs (Fig. 4A), whereas
the co-administration of RESV and HNE signiﬁcantly blunted superox-
ide production (Fig. 4A). Moreover, HNE treatment reduced the levels
of a surrogate marker for NO bioavailability, S-nitrosocysteine, in
HUVECs (Fig. 4B). While RESV treatment did not alter baseline
S-nitrosylation levels by HUVECs, RESV prevented the HNE-induced de-
crease in S-nitrosylation levels (Fig. 4B). HNEmarkedly reduced P-eNOS
levels in HUVECs (Fig. 4C), whereas co-treatment with RESV prevented
eNOS inhibition.
To understand the mechanisms regulating eNOS, we examined the
expression of regulators of eNOS phosphorylation in HUVECs. Consis-
tent with our analysis of arteries from hypertensive rodents (Fig. 3),
RESV increased P-AMPK 2-fold in control cells, while HNE markedly
inhibited P-AMPK in HUVECs (Fig. 4D). However, the co-treatmentof endothelial cells with HNE and RESV completely abrogated the in-
hibitory effects of HNE on P-AMPK. Since our previous work demon-
strated that HNE inhibited LKB1 activity [11], we also investigated
whether HNE altered levels of P-LKB1 in HUVECs. While HNE reduced
P-LKB1 levels, RESV completely prevented this decrease, which
resulted in a 2-fold increase in P-LKB1 levels (Fig. 4E). Since eNOS is
also phosphorylated at serine-1177 by Akt [31], we measured levels
of Akt phosphorylation in response to HNE. Unexpectedly, HNE treat-
ment of endothelial cells increased Akt phosphorylation, while the
treatment of cells with RESV and HNE attenuated HNE-induced
P-Akt (Fig. 4F). These data suggest that in HNE-treated HUVECs, Akt
activation alone is not sufﬁcient to induce eNOS phosphorylation. In
order to further investigate this pathway, AMPK was inhibited with
compound C and HUVECs were treated with HNE in combination
with RESV, as before. Interestingly compound C prevented the in-
crease in P-eNOS in the presence of RESV (Fig. 4G). Thus, it appears
that RESV stimulates the LKB1-AMPK signal transduction pathway
and not Akt, to prevent the HNE-induced inhibition of P-eNOS.
In order to determine whether eNOS activation was required for
AMPK activation by RESV, HUVECs were pre-treated with L-NAME,
followed by RESV. As expected, L-NAME did not prevent the stimula-
tion of P-AMPK by RESV (Fig. 4H). On the other hand, L-NAME pre-
treatment of HUVECs blocked the ability of RESV to prevent the
HNE-induced decrease in S-nitrosylation levels (Fig. 4I). Overall
these ﬁndings suggest that elevated HNE levels modiﬁed the
LKB1-AMPK-eNOS signal transduction cascade and reduced protein
nitrosylation, even in the absence of hypertension.3.4. Resveratrol prevents LVH in hypertensive rodents
Since RESV improved vascular function and prevented elevated BP,
we investigated whether RESV also prevented the development of
LVH in hypertensive rodents. Consistentwith the reduced hemodynam-
ic load, RESV treatment resulted in a substantial reduction in both the
heart weight/tibia length (HW/TL) ratio and the LV mass index in
SHRs (Fig. 5A, Table S1) and Ang-II infused mice (Fig. 5B, Table S2)
Fig. 3. Arterial signaling pathways in hypertensive rodents. Immunoblot analysis was performed on mesenteric artery homogenates isolated from Control-spontaneously hyperten-
sive rat (SHR) and resveratrol (RESV)-SHRs as well as saline or angiotensin (Ang)-II infused (1.4 mg/kg/day) mice that consumed control or RESV diets. Phosphorylated serine-1177
eNOS (P-eNOS) quantiﬁed by densitometry and normalized against total eNOS (A, B). Phosphorylated threonine-172 AMPK (P-AMPK) normalized against total AMPK (C, D). Phos-
phorylated serine-428 LKB1 (P-LKB1) normalized against total LKB1 (E, F). Serum levels of 4-hydroxy-2-nonenal (HNE)-protein adducts (G, H). Values are mean ± S.E.M. (n = 6).
**Signiﬁcant difference (p b 0.05) between Control-SHR and RESV-SHRs using Student's t-test. §Signiﬁcant difference (p b 0.05) between Control and RESV mice and a *signiﬁcant
difference (p b 0.05) between the AngII-Control group and other groups of mice using a two-way ANOVA with Bonferroni post-test.
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in LV posterior wall (LVPW) thickness in SHRs (Fig. 5C) and Ang-II in-
fused mice (Fig. 5D). Echocardiographic assessment revealed that
RESV did not signiﬁcantly inﬂuence HR or parameters of systolic (ejec-
tion fraction) and diastolic (intraventricular relaxation time; IVRT)
function in either the SHRs (Table S1) or the Ang-II infused mice(Table S2), comparedwith their respective controls. Nevertheless, stroke
work and LV wall stress of RESV-SHRs was signiﬁcantly lower than
control-SHRs (Fig. 5E, G). Infusion of mice with Ang-II increased stroke
work and LV wall stress, while RESV attenuated the effects of Ang-II on
the LV (Fig. 5F, H). Together, these results indicate that, RESV prevents
hypertension-induced LVH, likely secondary to preventing elevated BP.
Fig. 4. Regulation of nitric oxide production in response to resveratrol (RESV) and 4-hydroxy-2-nonenal (HNE) in human umbilical vein endothelial cells (HUVECs). HUVECs were
treated with 10 μM HNE, in combination with 10 μM RESV or vehicle-treated control (CON). Representative micrographs from three independent experiments are shown
for intracellular superoxide production determined by dihydroethidium staining in cells treated for 1 h (A) and immunostaining for nitrosocysteine in cells treated for 24 h (B).
Phosphorylated serine-1177 eNOS (P-eNOS) was quantiﬁed by densitometry and normalized against Actin (C). Phosphorylated threonine-172 AMPK (P-AMPK) was normalized
against total AMPK (D). Phosphorylated serine-428 LKB1 (P-LKB1) was normalized against total LKB1 (E). Phosphorylated serine-473 Akt (P-Akt) was normalized against total
Akt (F). P-eNOS in HUVECs pre-treated with compound C (1 μM) for 30 min (G). P-AMPK in HUVECs pre-treated with N-omega-nitro-L-arginine methyl ester (L-N; 200 μM) for
30 min followed by RESV treatment for 1 h (H). Nitrosocysteine levels in HUVECs pre-treated with L-N for 30 min (I). Representative immunoblot images from 3 to 5 independent
experiments are shown. *Signiﬁcant difference (p b 0.05) compared with CON. §Signiﬁcant difference (p b 0.05) compared with HNE treated cells.
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with the reduction of cardiac HNE and LVH
The p70S6 kinase (p70S6K) pathway regulates protein synthesis
and promotes hypertrophic growth of the myocardium [29]. Toinvestigatewhether RESV attenuated LVH through direct effects onmo-
lecular signaling cascades in the heart, we measured phosphorylated
levels of p70S6K (P-p70S6K) in SHRs since this pathway regulates pro-
tein synthesis and promotes hypertrophic growth of the myocardium
[29]. P-p70S6K was reduced in the hearts of RESV-SHRs compared to
Fig. 5. Cardiac morphometry and function of hypertensive rodents. Heart weight/tibia length (HW/TL) ratio (A, B). The change in left ventricular (LV) posterior wall thickness
(LVPW) calculated from the LVPW of individual rodents at baseline and following treatments using echocardiography (C, D). Stroke work (E, F). LV Wall stress (G, H). Values
are the mean ± S.E.M. (n = 6). **Signiﬁcant difference (p b 0.05) between Control-SHR and RESV-SHRs using Student's t-test. *Signiﬁcant difference (p b 0.05) between Control
(CON) and RESV mice and a §signiﬁcant difference (p b 0.05) between the AngII-CON group and other groups of mice using a two-way ANOVA with Bonferroni post-test.
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mice, P-p70S6K was higher than saline-controls, while RESV signiﬁ-
cantly reduced P-p70S6K (Fig. 6B). These results demonstrate an anti-
hypertrophic effect of RESV [11,29], whichwe previously demonstrated
to occur via the activation of AMPK [29]. In agreement with this, RESV
increased P-AMPK in SHRhearts (Fig. 6C).Moreover, Ang-II induced hy-
pertension reduced cardiac P-AMPK levels while RESV stimulated
P-AMPK in both saline and Ang-II infused mice (Fig. 6D). Consistent
with increases in P-AMPK levels, RESV increased P-LKB1 levels in hearts
from SHRs (Fig. 6E). Ang-II induced hypertension markedly inhibited
cardiac P-LKB1 levels while RESV prevented the inhibition of P-LKB1
(Fig. 6F). Since increased cardiac HNE levels were associated with re-
duced LKB1-AMPK signaling [11], we examined the effect of RESV on
HNE levels in the hearts of hypertensive rodents. RESV reduced cardiac
HNE concentrations in SHRs (Fig. 6G). Ang-II infusion elevated HNE
levels in the heart and RESV markedly attenuated this increase
(Fig. 6H).
4. Discussion
Herein, we provide evidence that RESV can prevent the rise in BP
in two distinct hypertensive rodent models, the SHR and Ang-II in-
fused mice. In both models, RESV induced several positive vascular
adaptations including reduced oxidative damage and improvedhyperemic vasodilation that correlated with activation of eNOS by
the LKB1-AMPK pathway. In addition, RESV contributed to reduced
oxidative damage to the heart, reduced cardiac LVH and inhibition
of pro-hypertrophic signaling pathways.
NO is the primary vasodilatory molecule in the circulation and
reduced NO bioavailability contributes to the pathogenesis of hyper-
tension [7]. A major factor that contributes to low NO bioavailability
is oxidative stress-mediated NO scavenging [7]. In fact, elevated
vascular ROS detrimentally affects endothelial function [5], which
precedes the development of hypertension. The generation of ROS is
a feature of hypertension in SHRs and Ang-II infused mice [9,32]. In
particular, the lipid peroxidation by-product, HNE, has been reported
to mediate damage due to ROS in endothelial cells [33]. Consistent
with this, we observed that Ang-II elevated HNE levels in the serum
and hearts of mice. Furthermore, we showed that in HUVECs, HNE
inhibited nitrosocysteine formation and enhanced the production of
superoxide by the cells. While it was previously reported that HNE
caused a dose-dependent inhibition of nitrite levels (a surrogatemarker
of NO bioavailability) in endothelial cells, the mechanism underlying
this observation was unknown [33]. Our data show that HNE inhibited
NOmediated nitrosocysteine formation possibly via reduced phosphor-
ylation of eNOS on serine-1177. While eNOS is phosphorylated and ac-
tivated by both AMPK and Akt [13,31], our data show that HNE inhibits
AMPK activation and stimulates Akt, suggesting that the inhibition of
Fig. 6. Signaling pathways that regulate myocardial growth in hypertensive rodents. Immunoblot analysis of ventricles isolated from spontaneously hypertensive rats (SHR) as well
as saline or angiotensin (Ang)-II infused (1.4 mg/kg/day) mice that consumed control or resveratrol (RESV) diets. Phosphorylated threonine-389 p70 S6 kinase (P-p70S6K) was
quantiﬁed by densitometry and normalized against tubulin (A, B). Phosphorylated threonine-172 AMPK (P-AMPK) was normalized against total AMPK (C, D). Phosphorylated
serine-428 LKB1 (P-LKB1) was normalized against total LKB1 (E, F). Cardiac 4-hydroxy-2-nonenal (HNE)-protein adducts (G, H). Values are mean ± S.E.M. (n = 6). **Signiﬁcant
difference (p b 0.05) between Control-SHR and RESV-SHRs using Student's t-test. *Signiﬁcant difference (p b 0.05) compared to the saline-Control group of mice and a §signiﬁcant
difference (p b 0.05) compared to the AngII-Control group using a two-way ANOVA with a Bonferroni post-test.
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thelial cells, LKB1 activity has been shown to correlate with its phos-
phorylation at serine-428 [30]. Consistent with the reduced P-AMPK,
P-LKB1 was also reduced by HNE, suggesting that HNE can directly in-
hibit LKB1 in the endothelium, similar to its effects in HEK293T cells
[12] and cardiac myocytes [11]. However, one major limitation to our
study is the fact that we were not successful in immunoprecipitating
LKB1 from mesenteric arteries or HUVECs. As such, we cannot provide
unequivocal evidence that HNE adducts are formed on LKB1 in hyper-
tensive rodents or whether RESV prevents this from occurring. Thatsaid, we have previously shown that HNE adducts are formed on LKB1
in the hearts of SHRs and that RESV can prevent these HNE adducts on
LKB1 and subsequently rescue LKB1-AMPK signaling [11]. These previ-
ous ﬁndings are consistent with the data provided herein showing that
RESV can lower HNE levels in the circulation of SHRs and Ang-II hyper-
tensive mice. However, we must acknowledge the fact that at present,
these ﬁndings are only correlative.
To investigate whether RESV increased NO bioavailability, we
treated cultured human endothelial cells with HNE in combination
with RESV. Notably, RESV attenuated the effects of HNE on superoxide
HNE 
Active Inactive LKB1 LKB1 
HNE 
Oxidative Stress 
Resveratrol 
AMPK 
eNOS p70S6K 
Inhibition of Protein  
Synthesis 
 and LV Hypertrophy 
Increased  NO  
Production 
and Improved  
Vascular Function 
Impaired 
Vascular Function 
LV 
Hypertrophy 
Fig. 7. Mechanism of 4-hydroxy-2-nonenal (HNE) and resveratrol actions in hypertensive rodents. In endothelial cells, active LKB1 stimulates AMP-activated protein kinase
(AMPK), which can phosphorylate and activate endothelial nitric oxide synthase (eNOS) [29]. In cardiac myocytes, active LKB1 stimulates AMPK which suppresses the activity
of p70 S6 kinase (p70S6K) and inhibits protein synthesis and cardiomyocyte hypertrophy [30]. Based on our ﬁndings, we propose that oxidative stress in the hypertensive rodents
contributes to elevated levels of HNE in the bloodstream and the heart. Within the vascular and cardiac tissues, HNE forms an adduct that inactivates the LKB1 kinase, reducing
eNOS activity and removing the restriction on p70S6K signaling. Together, these factors are associated with impaired vascular function and LV hypertrophy in the hypertensive
rodents. Resveratrol reduces circulating as well as cardiac levels of HNE levels, preventing the inactivation of LKB1. As a result, resveratrol activates AMPK which activates eNOS
and reduces p70S6K activity. Consequently, resveratrol contributes to improved vascular function and reduced LV hypertrophy in the hypertensive rodents.
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reduced HNE levels in the circulation of SHRs and Ang-II hypertensive
mice, which is consistent with the notion that the reduction of HNE
levels improves vascular function in hypertensive rodents. AMPK also
appears to be involved in this process since RESV activates AMPK and
AMPK directly phosphorylates eNOS, which increases NO production
[13]. However, it has also been shown that NO can activate AMPK, plac-
ing eNOS upstream of AMPK [34]. In contrast to the latter ﬁnding, our
study showed that the pre-treatment of HUVECs with L-NAME did not
block activation of AMPK by RESV. Moreover, inhibition of AMPK with
compound C prevented the phosphorylation of eNOS in response to
RESV treatment. In addition, other studies have shown that inhibition
of AMPKwith compound C abolishes the ability of RESV to improve en-
dothelium dependent vasodilation in aortic rings [35]. Furthermore,
L-NAME did not inhibit AMPK activation by RESV in the carotid arteries
of rats [36]. Together, our ﬁndings extend these previous observations
and identify a strong correlation between the stimulation of the
LKB1-AMPK-eNOS pathway and improved vasodilatory properties
both in cultured human endothelial cells and arteries isolated from
both SHRs and Ang-II induced hypertensive mice.
Isolated artery preparations were used to demonstrate that RESV
stimulated endothelium dependent relaxation [17,23,27,28]. Our results
conﬁrm these ﬁndings and extend them further to show that in two
different hypertensive rodentmodels, RESV improves ﬂow-mediated va-
sodilation in vivo. Vascular dysfunction is associated with high sys-
temic BP, suggesting that the ability of RESV to improve vascularfunction could contribute to lowering BP. Indeed, chronic RESV ad-
ministration reduced BP in DOCA-salt sensitive rats [20], partially
nephrectomized rats [22], and in two-kidney one-clip hypertensive
rats [21]. However, other studies showed that RESV did not affect
the BP of the SHR [11,17,18], stroke-prone SHR [16] or Dahl-salt sen-
sitive rat [19]. The differences between the in vivo effects of RESV in
hypertensive rodents are likely a consequence of different mechanisms
involved in the development of high BP in the various animal models,
the dose of RESV administered or the length of treatment. Our ﬁndings
demonstrate that chronic and high doses of RESV can prevent elevated
BP in SHRs, as well as in mice infused with Ang-II (Figs. 1, 2). Although
multiplemolecularmechanisms could be involved in the effects of RESV
on the vessels of hypertensive rodents [15], our results are consistent
with several reports that RESV stimulated eNOS in endothelial cells
[21,37,38]. Furthermore, we recently reported that RESV prevented
neointimal growth following vascular injury in wild-type mice, but
that this effect was lost in eNOS knock-out mice [36]. Together, these
data provide solid evidence that the beneﬁcial vascular effects of RESV
require activation of eNOS [36]. While the effects of RESV may extend
beyond NO bioavailability, we hypothesize that the rapid increase in
BP following the removal of RESV indicates NO-mediated effects as op-
posed to RESV-mediated suppression of remodeling of the artery wall
or changes in transcriptional levels of relevant genes.
As expected, the ability of RESV to prevent elevated BP also
protected the hearts of SHRs and Ang-II infused mice from LVH and
signiﬁcantly reduced the strain on the LV (Fig. 5). Previous studies
1732 V.W. Dolinsky et al. / Biochimica et Biophysica Acta 1832 (2013) 1723–1733showed that RESV prevented LVH in hypertensive rodents due to lower
SP [20–22]. However, RESVmay have direct effects on the growth of the
cardiac myocyte since RESV also prevented LVH in the absence of re-
duced BP in hypertensive rodents [11,16–19]. In this study, we did not
ascertain whether the effect of RESV on cardiac growth was mediated
via the reduction of BP or through direct effects on the growth of the
cardiac myocyte [29]. Nevertheless, our data supports the previous re-
port that RESV reduced cardiac HNE levels and prevented the inhibition
of LKB1-AMPK signaling [11]. Although we show that RESV was able to
prevent the development of hypertension and the resulting cardiac hy-
pertrophy, RESV treatment of hypertensive SHRs at 16 weeks of age did
not result in a regression of the phenotype (data not shown). While we
do not know the reasons for this, it is likely that once negative vascular
remodeling occurs, RESV is unable to reverse it (at least in the
short-term; i.e. 5 weeks). That said, although we did not test this in
the current study, it is possible that longer-term treatment with RESV
may improve the phenotype. Taken together, we suggest that chronic
administration of high dose RESV may reduce cardiac mass through
the reduction of BP as well as the inhibition of pro-hypertrophic signals
(p70S6K) and stimulate anti-hypertrophic signaling pathways (LKB1/
AMPK) in the cardiac myocyte.
5. Conclusions
Our data demonstrate that RESV improves vasodilatory function
and attenuates the development of hypertension in SHRs and Ang-II
infused mice. RESV induced improvements of vasodilatory functions
were associated with improved NO bioavailability. RESV also
reduced HNE levels in the hearts and circulation of hypertensive
SHRs and Ang-II infused mice, which was associated with an en-
hanced LKB1-AMPK-eNOS signaling pathway in isolated rodent arter-
ies and hearts (Fig. 7). These positive adaptations induced by RESV
likely contributed to the prevention of LVH. Recently, a clinical trial
showed that 30 days of RESV treatment reduced BP in overweight
middle-agedmen [39]. Based on these ﬁndings and our results, we pro-
pose that RESVmay be used as an additional approach for the treatment
of hypertension and associated LVH even in the absence of obesity.
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